GLP-1 Eligibility Calculator

Check whether your BMI and health conditions meet FDA label criteria for GLP-1 weight-loss medications such as Wegovy, Zepbound, and Saxenda.

Share this calculator

Height
Weight
Weight-related health conditions (optional)

31.14

BMI

90 kg

Weight

17.75 kg

To BMI 25

Likely eligible — BMI ≥ 30 Based on FDA label criteria, you may qualify for GLP-1 weight-loss medication. A prescribing clinician will make the final determination.

FDA-approved weight-loss medications you may qualify for:

Wegovy (semaglutide 2.4 mg)

First GLP-1 approved for chronic weight management in non-diabetic adults (2021).

Zepbound (tirzepatide 5–15 mg)

Dual GIP/GLP-1 receptor agonist; highest mean weight loss in pivotal trials to date (SURMOUNT-1).

Saxenda (liraglutide 3 mg)

First daily injectable GLP-1 approved for weight management (2014); now largely superseded by weekly injections.

This is not medical advice Eligibility is determined by a licensed clinician considering your full medical history. Insurance coverage, contraindications, and prior authorisation requirements also apply.

Also in Weight Loss Medication

GLP-1 Eligibility

GLP-1 Eligibility Calculator — am I eligible for Wegovy, Zepbound, or Ozempic?

FDA-approved GLP-1 weight-loss medications have specific eligibility criteria based on BMI and weight-related health conditions. This GLP-1 eligibility calculator checks whether your BMI meets the label criteria for Wegovy, Zepbound, and Saxenda — and shows which medications you may qualify for.

FDA eligibility criteria for GLP-1 weight medications

The FDA-approved labelling for weight-management GLP-1 drugs requires either: (a) BMI ≥ 30 kg/m² (obesity), or (b) BMI ≥ 27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes or prediabetes, dyslipidaemia, obstructive sleep apnoea, or established cardiovascular disease.

This criteria applies to Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3 mg). Note that Ozempic and Mounjaro are approved for type 2 diabetes management and are sometimes prescribed off-label for weight loss — different criteria may apply.

Insurance coverage and access

Meeting FDA eligibility criteria does not guarantee insurance coverage. Many US commercial insurers and Medicare Part D plans exclude obesity pharmacotherapy coverage or require prior authorisation, documented diet programme attempts, or additional comorbidity requirements.

Your prescribing clinician will also assess contraindications (e.g. personal/family history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis history) and your full medical history before prescribing.

Frequently asked questions

Can I get Ozempic for weight loss if I don't have diabetes?

Ozempic is FDA-approved for type 2 diabetes, not for weight management. Clinicians may prescribe it off-label, but insurance coverage for this indication is much less common. Wegovy (same molecule at higher dose) is the weight-management-approved form.

What BMI do I need for Wegovy or Zepbound?

BMI ≥ 30 (obesity class I or higher), or BMI ≥ 27 (overweight) plus at least one weight-related health condition such as high blood pressure, prediabetes, type 2 diabetes, high cholesterol, or sleep apnoea.

Related

More from nearby categories

These related calculators come from the same leaf category, nearby sibling categories, or the same top-level topic.